PRODIGY
Research type
Research Study
Full title
PRODIGY - PRediction of Opioid-induced respiratory Depression In patients monitored by capnoGraphY
IRAS ID
211590
Contact name
Christine Greening
Contact email
Sponsor organisation
Covidien Services Europe LTD
Duration of Study in the UK
0 years, 8 months, 1 days
Research summary
Opioid therapy is used as the primary intervention for managing pain in hospitals after surgery, it is indeed known as the gold standard for post surgical pain. One of the major opioid side effects includes respiratory depression (RD), which occurs when the respiration rate is slowed or stopped at all for a few seconds/minutes (apnea episodes). This can cause an inadequate ventilation of the lungs and consequently a low concentration of oxygen in the blood (SpO2).
To monitor and prevent RD episodes caused by opioid therapy, in addition to standard clinical practice a Medtronic Capnostream 20p bedside monitor will be used.Capnographic monitoring is approved by the authorities for use by doctors in the management of patients who have RD episodes caused by opioid therapy. It is routinely available as part of normal clinical care and is not experimental. The study will involve collecting information relating to the patients' condition and medical care, including information about their capnographic monitoring procedure
The purpose of this study is to improve the prediction of RD episodes in patients undergoing opioid therapy in the hospital ward (also known as the General Care Floor), and to guide clinicians and nursing staff in selecting the at-risk patients who could most benefit from capnographic monitoring
REC name
East of England - Cambridge Central Research Ethics Committee
REC reference
16/EE/0332
Date of REC Opinion
31 Aug 2016
REC opinion
Further Information Favourable Opinion